Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Clin. biomed. res ; 37(1): 33-37, 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-833278

RESUMEN

Introduction: Recent evidence shows that oxidative stress seems to be related with the pathophysiology of X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative disorder. Methods: In the present study, the in vitro effect of N-acetyl-L-cysteine (NAC) on glutathione (GSH) and sulfhydryl levels in X-ALD patients was evaluated. Results: A significant reduction of GSH and sulfhydryl content was observed in X-ALD patients compared to the control group. Furthermore, 5 mM of NAC, in vitro, led to an increase in GSH content and sulfhydryl groups in these patients. Conclusion: These data probably indicate that an adjuvant therapy with the antioxidant NAC could improve the oxidative imbalance in X-ALD patients(AU)


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Adulto , Persona de Mediana Edad , Acetilcisteína/farmacología , Adrenoleucodistrofia/fisiopatología , Glutatión/deficiencia , Compuestos de Sulfhidrilo/metabolismo , Adrenoleucodistrofia/tratamiento farmacológico , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo
2.
Indian J Pediatr ; 2009 Oct; 76(10): 1045-1047
Artículo en Inglés | IMSEAR | ID: sea-142400

RESUMEN

X-linked Adrenoleukodystrophy (ALD) is the most common of the peroxisomal disorder and is associated with functional defect of the very long chain fatty acid (VLCFA) oxidation leading to the accumulation of VLCFA in the white matter and adrenal cortex. Retrospective evaluation of medical records of ALD patients were carried out. In all the 5 patients the duration of the symptoms varied from 1-7 years. Most of them presented with Addisonian crisis (4/5) and hyperpigmentation (5/5), white half of them (3/5) had neurological symptoms. All patients had biochemical evidence of the adrenal insufficiency. All siblings of patients should be screened for the possibility of ALD with VLCFA.


Asunto(s)
Enfermedad de Addison/etiología , Enfermedad de Addison/fisiopatología , Corticoesteroides/uso terapéutico , Hormona Adrenocorticotrópica/sangre , Adrenoleucodistrofia/complicaciones , Adrenoleucodistrofia/diagnóstico , Adrenoleucodistrofia/tratamiento farmacológico , Adrenoleucodistrofia/genética , Análisis Químico de la Sangre , Niño , Preescolar , Ácidos Grasos no Esterificados/metabolismo , Estudios de Seguimiento , Humanos , Masculino , Estudios Retrospectivos , Medición de Riesgo , Muestreo , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA